The effects of nitric oxide (NO) on platelet membrane receptor expression during activation with human α-thrombin

Blood Coagulation and Fibrinolysis

Volumn 7, Issue 6, 1996, Pages 615-624

  Keh, D ^a   Gerlach, M ^a   Kurer I ^a   Seiler, S ^a   Kerner, T ^a   Falke, K J ^a   Gerlach, H ^a  

^a HUMBOLDT UNIVERSITY   (Germany)

Author keywords

flow cytometry; GP Ib; GP IIb IIIa; nitric oxide; P selectin; PAC 1; platelet; platelet membrane glycoproteins; SIN 1

Indexed keywords

GLYCOPROTEIN; LINSIDOMINE; MONOCLONAL ANTIBODY; NITRIC OXIDE; PADGEM PROTEIN; THROMBIN; THROMBOCYTE RECEPTOR;

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETRY; HOMEOSTASIS; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE FUNCTION;

EID: 0029963364     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-199609000-00007     Document Type: Article

References (56)

1. Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemostasts 1993; 70: 36-41.
2. Radomski MW, Palmer RM, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; 2: 1057-1058.
3. Venturini CM, Weston LK, Kaplan JE. Platelet cGMP, but not cAMP, inhibits thrombin-induced platelet adhesion to pulmonary vascular endothelium. Am J Physiol 1992; 263: H606-H612.
4. Siney L, Lewis MJ. Endothelium-derived relaxing factor inhibits platelet adhesion to cultured porcine endocardial endothelium. Eur J Pharmacol 1992; 229: 223-226.
5. Radomski MW, Vallance P, Whitley G, Foxwell N, Moncada S. Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide. Cardiovasc Res 1993; 27: 1380-1382.
6. Radomski MW, Palmer RM, Moncada S. Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987; 92: 181-187.
7. Houston DS, Robinson P, Gerrard JM. Inhibition of intravascular platelet aggregation by endothelium-derived relaxing factor: reversal by red blood cells. Blood 1990; 76: 953-958.
8. Macdonald PS, Read MA, Dusting GJ. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin. Thromb Res 1988; 49: 437-449.
9. Furlong B, Henderson AH, Lewis MJ, Smith JA. Endothelium-derived relaxing factor inhibits in vitro platelet aggregation. Br J Pharmacol 1987; 90: 687-692.
10. Radomski MW, Palmer RMJ, Moncada S. The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987; 92: 639-646.
11. Högman M, Frostell C, Arnberg H, Sandhagen B, Hedenstierna G. Prolonged bleeding time during nitric oxide inhalation in the rabbit. Acta Physiol Scand 1994; 151: 125-129.
12. Högman M, Frostell C, Arnberg H, Hedenstierna G. Bleeding time prolongation and NO inhalation. Lancet 1993; 341: 1664-1665.
13. Samama CM, Diaby M, Fellahi JL, et al. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome, Anesthesiology 1995; 83: 56-65.
14. de Graaf JC, Banga JD, Moncada S, Palmer RM, de Groot PG, Sixma JJ. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions. Circulation 1992; 85: 2284-2290.
15. Pohl U, Busse R. EDRF increases cyclic GMP in platelets during passage through the coronary vascular bed. Circ Res 1989; 65: 1798-1803.
16. Golino P, Cappelli Bigazzi M, Ambrosio G, et al. Endothelium-derived relaxing factor modulates platelet aggregation in an in vivo model of recurrent platelet activation. Circ Res 1992; 71: 1447-1456.
17. Bhardwaj R, Page CP, May GR, Moore PK. Endothelium-derived relaxing factor inhibits platelet aggregation in human whole blood in vitro and in the rat in vivo. Eur J Pharmacol 1988; 157: 83-91.
18. May GR, Crook P, Moore PK, Page CP. The role of nitric oxide as an endogenous regulator of platelet and neutrophil activation within the pulmonary circulation of the rabbit. Br J Pharmacol 1991; 102: 759-763.
19. 1. J Cardiovasc Pharmacol 1991; 17: 424-433.
20. Gerzer R, Karrenbrock B, Siess W, Heim JM. Direct comparison of the effects of nitroprusside, SIN 1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity. Thromb Res 1988; 52: 11-21.
21. Radomski MW, Rees DD, Dutra A, Moncada S. S-nitroso-glutathione inhibits platelet activation in vitro and in vivo. Br J Pharmacol 1992; 107: 745-749.
22. Salas E, Moro MA, Askew S, et al. Comparative pharmacology of analogues of S-nitroso-N-acetyl-DL-penicillamine on human platelets. Br J Pharmacol 1994; 112: 1071-1076.
23. Hines R, Barash PG. Infusion of sodium nitroprusside induces platelet dysfunction in vitro. Anesthesiology 1989; 70: 611-615.
24. Radomski MW, Palmer RM, Moncada S. Characterization of the L-arginine: nitric oxide pathway in human platelets. Br J Pharmacol 1990; 101: 325-328.
25. Radomski MW, Palmer RM, Moncada S. An L-arginine/nitric oxide pathway present in human platelets regulates aggregation. Proc Natl Acad Sci USA 1990; 87: 5193-5197.
26. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 1981; 57: 946-955.
27. Durante W, Kroll MH, Vanhoutte PM, Schafer AI. Endothelium-derived relaxing factor inhibits thrombin-induced platelet aggregation by inhibiting platelet phospholipase C. Blood 1992; 79: 110-116.
28. Maurice DH, Haslam RJ. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 1990; 37: 671-681.
29. Nguyen BL, Saitoh M, Ware AJ. Interaction of nitric oxide and cGMP with signal transduction in activated platelets. Am J Physiol 1991; 261: H1043-H1052.
30. Langford EJ, Brown AS, Wainwright RJ, et al. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet 1994; 344: 1458-1460.
31. Freedman JE, Loscalzo J, Benoit SE, Valeri CR, Barnard MR, Michelson AD. Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis. J Clin Invest 1996; 97: 979-987.
32. Michelson AD, Benoit SE, Furman MI, et al. Effects of nitric oxide/EDRF on platelet glycoproteins. Am J Physiol 1996; 270: H1640-H1648.
33. Berman CL, Yeo EL, Wencel Drake JD, Furie BC, Ginsberg MH, Furie B. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation. Characterization and sub-cellular localization of platelet activation-dependent granule-external membrane protein. J Clin Invest 1986; 78: 130-137.
34. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemostasis 1991; 65: 467-473.
35. Ginsberg MH, Xiaoping D, O'Toole TE, Loftus JC, Plow EF. Platelet integrins. Thromb Haemostasis 1993; 70: 87-93.
36. Plow EF, McEver RP, Coller BS, Woods VL, Jr, Marguerie GA, Ginsberg MH. Related binding mechanisms for fibrinogen, fibronectin, von Willebrand factor, and thrombospondin on thrombin-stimulated human platelets. Blood 1985; 66: 724-727.
37. Woods VL Jr, Wolff LE, Keller DM. Resting platelets contain a substantial centrally located pool of glycoprotein IIb-IIIa complex which may be accessible to some but not other extracellular proteins. J Biol Chem 1986; 261: 15242-15251.
38. Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood 1987; 70: 307-315.
39. Sims PJ, Ginsberg MH, Plow EF, Shattil SJ. Effect of platelet activation on the conformation of the plasma membrane glycoproteib IIb-IIIa complex. J Biol Chem 1991; 266: 7345-7352.
40. Shattil SJ, Hoxie JA, Cunningham M, Brass LF. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation. J Biol Chem 1985; 260: 11107-11114.
41. Hourdille P, Heilmann E, Combrie R, Winckler J, Clemetson KJ, Nurden AT. Thrombin induces a rapid redistribution of glycoprotein Ib-IX complexes within the membrane systems of activated human platelets. Blood 1990; 76: 1503-1513.
42. Michelson AD, Benoit SE, Kroll MH, et al. The activation-induced decrease in the platelet surface expression of the glycoprotein Ib-IX complex is reversible. Blood 1994; 83: 3562-3573.
43. Fox JE. Shedding of adhesion receptors from the surface of activated platelets. Blood Coag Fibrinol 1994; 5: 291-304.
44. Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of the peptide GPRP and flow cycometry: methods and clinical applications. Blood Coag Fibrinol 1994; 5: 121-131.
45. Feelisch M, Ostrowski J, Noack E. On the mechanism of NO release from sydnonimines. J Cardiovasc Pharmacol 1989; 14: S13-S22.
46. Moro MA, Darley-Usmar VM, Goodwin DA, et al. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci USA 1994; 91: 6702-6706.
47. Brass LF, Manning DR, Shattil SJ. GTP-binding proteins and platelet activation. In: Coller BS, ed. Progress in Hemostasis and Thrombosis. Philadelphia: W. B. Saunders, 1991: 127-174.
48. Golden A, Brugge JS, Shattil SJ. Role of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet proteins. J Cell Biol 1990; 111: 3117-3127.
49. Parise LV, Criss AB, Nannizzi L, Wardell MR. Glycoprotein IIIa is phosphorylated in intact human platelets. Blood 1990; 75: 2363-2368.
50. Fox JE. Transmembrane signaling across the platelet integrin glycoprotein IIb-IIIa. Ann NY Acad Sci 1994; 714: 75-87.
51. Peerschke EI, Zucker MB, Grant RA, Egan JJ, Johnson MM. Correlation between fibrinogen binding to human platelets and platelet aggregability. Blood 1980; 55: 841-847.
52. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 71: 831-843.
53. Shahbazi T, Jones N, Radomski MW, Moro MA, Gingell D. Nitric oxide donors inhibit platelet spreading on surfaces coated with fibrinogen but not with fibronectin. Thromb Res 1994; 75: 631-642.
54. van Willigen G, Akkermann JWN. Regulation of glycoprotein IIb/IIIa exposure on platelets stimulated with α-thrombin. Blood 1992; 79: 82-90.
55. Gopalakrishna R, Chen ZH, Gundimeda U. Nitric oxide and nitric oxide-generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding. J Biol Chem 1993; 268: 27180-27185.
56. Clemetson KJ, Clemetson JM. Platelet GPIb-V-IX complex. Structure, function, physiology, and pathology. Semin Thromb Hemost 1995; 21: 130-136.